Raquel A C Machado1, Dunja Stojevski1, Sébastien De Landtsheer2, Philippe Lucarelli2,3, Alexandre Baron1,4, Thomas Sauter2, Elisabeth Schaffner-Reckinger5. 1. Cancer Cell Biology and Drug Discovery Group, Department of Life Sciences and Medicine, Faculty of Science, Technology and Medicine, University of Luxembourg, CAMPUS Belval, BT1, 7, avenue des Hauts-Fourneaux, 4362, Esch-sur-Alzette, Luxembourg. 2. Systems Biology Group, Department of Life Sciences and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg. 3. Sensile Medical AG, Olten, Switzerland. 4. Immune Systems Biology Group, Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg. 5. Cancer Cell Biology and Drug Discovery Group, Department of Life Sciences and Medicine, Faculty of Science, Technology and Medicine, University of Luxembourg, CAMPUS Belval, BT1, 7, avenue des Hauts-Fourneaux, 4362, Esch-sur-Alzette, Luxembourg. elisabeth.schaffner@uni.lu.
Abstract
BACKGROUND: Metastasis is the predominant cause for cancer morbidity and mortality accounting for approximatively 90% of cancer deaths. The actin-bundling protein L-plastin has been proposed as a metastatic marker and phosphorylation on its residue Ser5 is known to increase its actin-bundling activity. We recently showed that activation of the ERK/MAPK signalling pathway leads to L-plastin Ser5 phosphorylation and that the downstream kinases RSK1 and RSK2 are able to directly phosphorylate Ser5. Here we investigate the involvement of the PI3K pathway in L-plastin Ser5 phosphorylation and the functional effect of this phosphorylation event in breast cancer cells. METHODS: To unravel the signal transduction network upstream of L-plastin Ser5 phosphorylation, we performed computational modelling based on immunoblot analysis data, followed by experimental validation through inhibition/overexpression studies and in vitro kinase assays. To assess the functional impact of L-plastin expression/Ser5 phosphorylation in breast cancer cells, we either silenced L-plastin in cell lines initially expressing endogenous L-plastin or neoexpressed L-plastin wild type and phosphovariants in cell lines devoid of endogenous L-plastin. The established cell lines were used for cell biology experiments and confocal microscopy analysis. RESULTS: Our modelling approach revealed that, in addition to the ERK/MAPK pathway and depending on the cellular context, the PI3K pathway contributes to L-plastin Ser5 phosphorylation through its downstream kinase SGK3. The results of the transwell invasion/migration assays showed that shRNA-mediated knockdown of L-plastin in BT-20 or HCC38 cells significantly reduced cell invasion, whereas stable expression of the phosphomimetic L-plastin Ser5Glu variant led to increased migration and invasion of BT-549 and MDA-MB-231 cells. Finally, confocal image analysis combined with zymography experiments and gelatin degradation assays provided evidence that L-plastin Ser5 phosphorylation promotes L-plastin recruitment to invadopodia, MMP-9 activity and concomitant extracellular matrix degradation. CONCLUSION: Altogether, our results demonstrate that L-plastin Ser5 phosphorylation increases breast cancer cell invasiveness. Being a downstream molecule of both ERK/MAPK and PI3K/SGK pathways, L-plastin is proposed here as a potential target for therapeutic approaches that are aimed at blocking dysregulated signalling outcome of both pathways and, thus, at impairing cancer cell invasion and metastasis formation. Video abstract.
BACKGROUND: Metastasis is the predominant cause for cancer morbidity and mortality accounting for approximatively 90% of cancer deaths. The actin-bundling protein L-plastin has been proposed as a metastatic marker and phosphorylation on its residue Ser5 is known to increase its actin-bundling activity. We recently showed that activation of the ERK/MAPK signalling pathway leads to L-plastin Ser5 phosphorylation and that the downstream kinases RSK1 and RSK2 are able to directly phosphorylate Ser5. Here we investigate the involvement of the PI3K pathway in L-plastin Ser5 phosphorylation and the functional effect of this phosphorylation event in breast cancer cells. METHODS: To unravel the signal transduction network upstream of L-plastin Ser5 phosphorylation, we performed computational modelling based on immunoblot analysis data, followed by experimental validation through inhibition/overexpression studies and in vitro kinase assays. To assess the functional impact of L-plastin expression/Ser5 phosphorylation in breast cancer cells, we either silenced L-plastin in cell lines initially expressing endogenous L-plastin or neoexpressed L-plastin wild type and phosphovariants in cell lines devoid of endogenous L-plastin. The established cell lines were used for cell biology experiments and confocal microscopy analysis. RESULTS: Our modelling approach revealed that, in addition to the ERK/MAPK pathway and depending on the cellular context, the PI3K pathway contributes to L-plastin Ser5 phosphorylation through its downstream kinase SGK3. The results of the transwell invasion/migration assays showed that shRNA-mediated knockdown of L-plastin in BT-20 or HCC38 cells significantly reduced cell invasion, whereas stable expression of the phosphomimetic L-plastin Ser5Glu variant led to increased migration and invasion of BT-549 and MDA-MB-231 cells. Finally, confocal image analysis combined with zymography experiments and gelatin degradation assays provided evidence that L-plastin Ser5 phosphorylation promotes L-plastin recruitment to invadopodia, MMP-9 activity and concomitant extracellular matrix degradation. CONCLUSION: Altogether, our results demonstrate that L-plastin Ser5 phosphorylation increases breast cancer cell invasiveness. Being a downstream molecule of both ERK/MAPK and PI3K/SGK pathways, L-plastin is proposed here as a potential target for therapeutic approaches that are aimed at blocking dysregulated signalling outcome of both pathways and, thus, at impairing cancer cell invasion and metastasis formation. Video abstract.
Authors: Guangxin Ma; Deniz Gezer; Oliver Herrmann; Kristina Feldberg; Mirle Schemionek; Mohamad Jawhar; Andreas Reiter; Tim H Brümmendorf; Steffen Koschmieder; Nicolas Chatain Journal: Mol Carcinog Date: 2019-11-06 Impact factor: 4.784
Authors: A Lapillonne; O Coué; E Friederich; A Nicolas; L Del Maestro; D Louvard; S Robine; X Sastre-Garau Journal: Anticancer Res Date: 2000 Sep-Oct Impact factor: 2.480
Authors: Meenakshi A Chellaiah; Megan C Moorer; Sunipa Majumdar; Hanan Aljohani; Sharon C Morley; Vanessa Yingling; Joseph P Stains Journal: Bone Res Date: 2020-01-22 Impact factor: 13.567
Authors: Emre Balta; Robert Hardt; Jie Liang; Henning Kirchgessner; Christian Orlik; Beate Jahraus; Stefan Hillmer; Stefan Meuer; Katrin Hübner; Guido H Wabnitz; Yvonne Samstag Journal: Nat Commun Date: 2019-09-09 Impact factor: 14.919